Metazide

Metazide

SCHEMBL2109857

O=C(NNCNNC(=O)c1ccncc1)c1ccncc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.72
HDAC3 O15379 1/20 0.64
HDAC1 Q13547 1/20 0.64
HDAC2 Q92769 1/20 0.64
KDM4E B2RXH2 2/20 0.61
MPO P05164 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
ADORA3 P0DMS8 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2A6 P11509 1/20 0.61
CYP2C19 P33261 1/20 0.61
TP53 P04637 1/20 0.60
CA1 P00915 2/20 0.56
CA9 Q16790 2/20 0.56
MAOA P21397 1/20 0.56
MAOB P27338 1/20 0.56
PTGS2 P35354 1/20 0.56
GAA P10253 2/20 0.53
HPGD P15428 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2992964 0.84 ALDH1A1 (1.00) ALDH1A1KDM4EMPOCYP1A2CYP3A4
SCHEMBL2992612 0.84 HDAC3 (0.70) ALDH1A1HDAC3HDAC1HDAC2KDM4E
SCHEMBL2998521 0.82 HDAC3 (0.68) ALDH1A1HDAC3HDAC1HDAC2KDM4E
SCHEMBL2998085 0.82 ALDH1A1 (0.64) ALDH1A1HDAC3HDAC1HDAC2KDM4E
SCHEMBL3001447 0.81 HDAC3 (0.81) ALDH1A1HDAC3HDAC1HDAC2KDM4E
SCHEMBL14113829 0.81 ALDH1A1 (0.62) ALDH1A1HDAC3HDAC1HDAC2KDM4E
SCHEMBL3935113 0.81 ALDH1A1 (0.62) ALDH1A1HDAC3HDAC1HDAC2KDM4E
SCHEMBL2992615 0.80 MAOA (0.62) ALDH1A1HDAC3HDAC1HDAC2KDM4E
Methaniazide SCHEMBL606355 0.80 ALDH1A1 (0.60) ALDH1A1HDAC3HDAC1HDAC2KDM4E
SCHEMBL2989666 0.80 ALDH1A1 (0.60) ALDH1A1HDAC3HDAC1HDAC2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
CN-119101649-A MZ B cell over-expressing Hspa13 gene and application thereof 中国人民解放军军事科学院军事医学研究院 2024-12-10 CN disclosed
CN-114605297-B Aryl sulfide containing substituted benzylamine structure, composition and application thereof 海利尔药业集团股份有限公司 2024-01-02 CN disclosed
CN-114957062-B Para-substituted biphenyl thioether compound, composition and application thereof 海利尔药业集团股份有限公司 2023-12-29 CN disclosed
CN-113563322-B Substituted benzamide isoxazoline derivative or salt acceptable as pesticide, composition and application thereof 海利尔药业集团股份有限公司 2023-07-07 CN disclosed
CN-116096696-A Compositions, agrochemicals, methods for increasing water and nutrient availability and improving pest control in plants and seeds, and uses of said compositions and said agrochemicals 奥克西泰诺工业和贸易公司 2023-05-09 CN disclosed
CN-114615890-A Herbicidal mixtures comprising aminopyridine and quinmerac 安道麦阿甘有限公司 2022-06-10 CN disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 ALDH1A1 4549/4885HDAC3 4406/4885HDAC1 4257/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 ALDH1A1 4459/4885HDAC3 3908/4885HDAC1 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.